

# PEMBROLIZUMAB AND IMMUNE MEDIATED NEPHRITIS: A CASE REPORT

Calleja Chuclá T, Mondelo García C, Busto Fernández F, Mateos Salvador M, Fernández Gabriel E, Martín Herranz I

Servicio de Farmacia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 84. 15006 A Coruña, Spain.

## Background

- ❖ Pembrolizumab is a selective humanized IgG4 monoclonal antibody known as a programmed cell death 1 (PD-1) immune checkpoint inhibitor. It is the First PD-1 Inhibitor approved for Unresectable or Metastatic Melanoma. With the arrival of this new mechanism of action also arrived immune-mediated adverse reactions.


## Purpose

- ❖ To describe a immune mediated nephritis in a diagnosed nodular melanoma patient that was being treated with pembrolizumab as a secondline treatment.

## Material and methods

Descriptive and retrospective clinical case  
Data were obtained by review of the electronic medical records

## Results



**Karch-Lasagna algorithm**

Stablishes

A "**POSIBLE**" relationship between nephritis and pembrolizumab based on **temporal correlation** between the start of the treatment and the nephritis appearance, as well as the treatment discontinuation and the nephritis improvement.

## Conclusions

- ❖ Health professionals must be vigilant in identifying drug related adverse reactions, particularly those related to drugs on the European list of medicinal products under additional monitoring.
- ❖ Nephritis has been reported in patients receiving pembrolizumab, patients should be monitored for changes in renal function and other causes of renal dysfunction should be excluded.
- ❖ In our case, creatinine dramatically increased after the third cycle of treatment with pembrolizumab (onset of three months) and it has continuously decreased since pembrolizumab discontinuation, eventually reaching normal range.